Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 25.8
(-3.01%)
SEK 25.8
(-3.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 135.91 Million SEK | 14.83% |
| 2022 | 118.01 Million SEK | 11.53% |
| 2021 | 105.8 Million SEK | -1.16% |
| 2020 | 107.05 Million SEK | 2.87% |
| 2019 | 104.07 Million SEK | 6.79% |
| 2018 | 97.45 Million SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 40.73 Million SEK | 18.4% |
| 2024 Q3 | 59.51 Million SEK | 9.58% |
| 2024 Q1 | 34.4 Million SEK | 1.33% |
| 2023 FY | 135.51 Million SEK | 14.83% |
| 2023 Q3 | 33.56 Million SEK | -3.94% |
| 2023 Q2 | 34.93 Million SEK | 5.67% |
| 2023 Q1 | 33.06 Million SEK | 13.22% |
| 2023 Q4 | 33.94 Million SEK | 1.15% |
| 2022 Q2 | 33.87 Million SEK | 28.87% |
| 2022 Q1 | 26.28 Million SEK | 44.97% |
| 2022 Q3 | 28.56 Million SEK | -15.7% |
| 2022 FY | 118.01 Million SEK | 11.53% |
| 2022 Q4 | 29.2 Million SEK | 2.24% |
| 2021 Q4 | 18.13 Million SEK | -40.88% |
| 2021 Q3 | 30.67 Million SEK | 1.22% |
| 2021 Q2 | 30.3 Million SEK | 17.75% |
| 2021 Q1 | 25.73 Million SEK | 7.06% |
| 2021 FY | 105.8 Million SEK | -1.16% |
| 2020 Q4 | 24.03 Million SEK | -3.15% |
| 2020 Q2 | 30.64 Million SEK | 22.7% |
| 2020 FY | 107.05 Million SEK | 2.87% |
| 2020 Q1 | 24.97 Million SEK | -15.31% |
| 2020 Q3 | 24.82 Million SEK | -19.01% |
| 2019 Q3 | 24.63 Million SEK | -3.95% |
| 2019 Q4 | 29.49 Million SEK | 19.75% |
| 2019 FY | 104.07 Million SEK | 6.79% |
| 2019 Q2 | 25.64 Million SEK | 13.74% |
| 2019 Q1 | 22.54 Million SEK | 0.0% |
| 2018 FY | 97.45 Million SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 91.024% |
| Camurus AB (publ) | 1.05 Billion SEK | 87.174% |
| Mendus AB (publ) | 129.13 Million SEK | -5.246% |
| Lipum AB (publ) | 37.3 Million SEK | -264.307% |
| NextCell Pharma AB | -576.01 Thousand SEK | 23695.055% |
| Simris Alg AB (publ) | 38.64 Million SEK | -251.721% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -379.808% |
| Active Biotech AB (publ) | 44.8 Million SEK | -203.314% |
| Amniotics AB (publ) | 29.07 Million SEK | -367.501% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -827.537% |
| BioArctic AB (publ) | 89.62 Million SEK | -51.642% |
| Cantargia AB (publ) | 290.01 Million SEK | 53.137% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -520.744% |
| CombiGene AB (publ) | 44.14 Million SEK | -207.883% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 4.948% |
| Genovis AB (publ.) | 88.19 Million SEK | -54.1% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -18.109% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1770.006% |
| Intervacc AB (publ) | 79.78 Million SEK | -70.348% |
| Kancera AB (publ) | 63.07 Million SEK | -115.47% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -2362.62% |
| LIDDS AB (publ) | 27.75 Million SEK | -389.738% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1773.615% |
| OncoZenge AB (publ) | 15.9 Million SEK | -754.524% |
| Saniona AB (publ) | 1.07 Million SEK | -12519.499% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 57.726% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 61.996% |
| Xintela AB (publ) | 57.31 Million SEK | -137.128% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 25.214% |
| Ziccum AB (publ) | 27.87 Million SEK | -387.524% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -728.681% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 55.742% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -218.803% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -668.603% |
| Corline Biomedical AB | 30.16 Million SEK | -350.517% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -134.206% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -63.417% |
| Aptahem AB (publ) | 10.01 Million SEK | -1257.363% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -0.904% |
| Fluicell AB (publ) | 28.61 Million SEK | -374.934% |
| Biovica International AB (publ) | 133.72 Million SEK | -1.638% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -586.771% |
| AcouSort AB (publ) | 25.87 Million SEK | -425.243% |
| Abliva AB (publ) | 27.86 Million SEK | -387.734% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 29.761% |
| 2cureX AB (publ) | 36.51 Million SEK | -272.178% |
| I-Tech AB | 40.14 Million SEK | -238.527% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 84.186% |
| Cyxone AB (publ) | 28.21 Million SEK | -381.718% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -24.27% |
| Biosergen AB | 26.8 Million SEK | -406.964% |
| Nanologica AB (publ) | 69.88 Million SEK | -94.474% |
| SynAct Pharma AB | 224.49 Million SEK | 39.459% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -207.66% |
| BioInvent International AB (publ) | 441.4 Million SEK | 69.209% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -467.381% |
| Alzinova AB (publ) | 36.39 Million SEK | -273.426% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 53.093% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1629.981% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -22.538% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -824.571% |